First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals
Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market
https://finance.yahoo.com/healthcare/articles...00124.html